Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q2
$6.98M Buy
218,939
+986
+0.5% +$31.1K 0.12% 107
2017
Q1
$7.07M Sell
217,953
-8,543
-4% -$269K 0.13% 107
2016
Q4
$6.98M Sell
226,496
-3,605
-2% -$110K 0.14% 99
2016
Q3
$7.39M Buy
230,101
+18,754
+9% +$627K 0.14% 102
2016
Q2
$7.06M Buy
211,347
+6,882
+3% +$220K 0.14% 100
2016
Q1
$5.75M Buy
204,465
+30
+0% +$857 0.12% 106
2015
Q4
$6.26M Sell
204,435
-21
-0% -$661 0.12% 104
2015
Q3
$6.09M Buy
204,456
+2,200
+1% +$70.5K 0.12% 108
2015
Q2
$6.43M Buy
202,256
+1,115
+0.6% +$36.3K 0.11% 114
2015
Q1
$6.64M Sell
201,141
-2,289
-1% -$72.8K 0.12% 111
2014
Q4
$6.01M Sell
203,430
-10,380
-5% -$298K 0.11% 113
2014
Q3
$6M Buy
213,810
+6,965
+3% +$195K 0.11% 117
2014
Q2
$5.83M Buy
206,845
+23,585
+13% +$672K 0.11% 121
2014
Q1
$5.58M Buy
183,260
+113,066
+161% +$3.37M 0.1% 114
2013
Q4
$2.04M Sell
70,194
-2,790
-4% -$81.2K 0.04% 160
2013
Q3
$1.99M Buy
72,984
+12,885
+21% +$351K 0.04% 167
2013
Q2
$1.6M Buy
+60,099
New +$1.66M 0.04% 168

Other funds holding PFE

Geneva Advisors's PFE Position: Q2 2017 in Review

Geneva Advisors increased its Pfizer (PFE) stake by 0.45% in Q2 2017, buying an estimated $31.1K and bringing the position to 218,939 shares worth $6.98M. The position accounts for 0.12% of the portfolio, ranked #107.

Geneva Advisors first reported a position in PFE in Q2 2013 and has held it in 17 quarters since. The position peaked at $7.39M in Q3 2016. 2,049 funds tracked by Wall St. Rank hold PFE as of Q2 2017.

  • Geneva Advisors held 218,939 shares of Pfizer worth $6.98M as of Q2 2017.
  • Geneva Advisors bought 986 Pfizer shares in Q2 2017, an estimated $31.1K.
  • Pfizer made up 0.12% of Geneva Advisors's portfolio in Q2 2017, its #107 holding.
  • Geneva Advisors first reported a position in Pfizer in Q2 2013 and has held it in 17 quarters since.
  • Geneva Advisors's Pfizer position peaked at $7.39M in Q3 2016.
  • 2,049 funds tracked by Wall St. Rank held Pfizer as of Q2 2017.

Based on Geneva Advisors's 13F filing for Q2 2017, filed 7 Aug 2017.